Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report sent to investors on Thursday, MarketBeat reports. The firm issued a buy rating and a $38.00 price target on the stock.

Several other research firms have also issued reports on JSPR. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. HC Wainwright cut their price objective on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. Finally, Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $64.44.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $6.08 on Thursday. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The company’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $17.52. The stock has a market capitalization of $91.20 million, a PE ratio of -1.28 and a beta of 2.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Jasper Therapeutics in the third quarter worth about $251,000. Samsara BioCapital LLC raised its holdings in shares of Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares in the last quarter. Barclays PLC boosted its position in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics in the third quarter valued at $447,000. Finally, Ally Bridge Group NY LLC increased its position in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.